Sun Pharmaceutical Industries Announcements
Newspaper Advertisements for Unaudited Financial Results for the quarter and nine months ended 31 December 2025
01 Feb, 2026 | 01:31pm • Source: BSE
Q3FY26 Earnings Call audio recording
31 Jan, 2026 | 08:21pm • Source: BSE
Board of Directors of the Company has approved the re-appointment of Dr. Pawan Goenka as Independent director for a second term of five years effective...
31 Jan, 2026 | 05:39pm • Source: BSE
Board has approved the interim dividend for FY 2025-26
31 Jan, 2026 | 02:30pm • Source: BSE
Unaudited Financial Results for the quarter and nine months ended 31 December 2025
31 Jan, 2026 | 02:26pm • Source: BSE
Press release regarding intimation of DCGI approval to manufacture and market generic semaglutide injection in India for chronic weight management
23 Jan, 2026 | 08:21am • Source: BSE
Response to Rumour verification letter from BSE
19 Jan, 2026 | 12:46pm • Source: BSE
The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on January 19, 2026, with reference to news appeared in https://www.news18.com/ dated January 19, 2026...
19 Jan, 2026 | 10:55am • Source: BSE
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India
14 Jan, 2026 | 02:41pm • Source: BSE
Intimation regarding Certificate of Compliance
09 Jan, 2026 | 07:46pm • Source: BSE
SPIL Investor Presentation -Dec 2025
26 Dec, 2025 | 02:51pm • Source: BSE
Newspaper Advertisement
23 Dec, 2025 | 01:10pm • Source: BSE
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 US FDA determines Baska facility inspection classification as OAI
18 Dec, 2025 | 10:02am • Source: NSE
US FDA determines Baska facility inspection classification as OAI
18 Dec, 2025 | 08:25am • Source: BSE
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated December 01, 2025, titled "Sun Pharma introduces its global innovative drug, Ilumya®...
01 Dec, 2025 | 10:04am • Source: NSE
Sun Pharma introduces Ilumya in India for the treatment of moderate-to-severe Plaque Psoriasis.
01 Dec, 2025 | 09:11am • Source: BSE
Press Release
26 Nov, 2025 | 10:29am • Source: BSE
Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated November 26, 2025
26 Nov, 2025 | 09:39am • Source: NSE
AstraZeneca Pharma India and Sun Pharma partner to help patients living with Hyperaklaemia in India
17 Nov, 2025 | 04:05pm • Source: BSE